iCellate Medical Ramps Up Prostate Study with Capio Urology Center
Stockholm, Sweden – April 18, 2023 – iCellate continues validation of its circulating tumor cell (CTC) platform CellMate® across various cancer indications. In collaboration with Capio Urology Center in Liljeholmen, Sweden, iCellate launches study to investigate the clinical value of CTC analysis in prostate cancer patients at various stages of disease.Despite prostate cancer being one of the most common cancers in men, the question of whether to implement prostate cancer screening remains unanswered. As is the case for many cancers, the characterization and treatment of prostate cancer is